NCT03233711 2026-03-18
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
9 trialsNCT04166318 2026-03-02
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT03403465 2026-02-27
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
Duke University
Phase 2 Active not recruiting
NCT06640283 2025-12-24
ANA
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT05040815 2025-10-02
INSPIRE
AHS Cancer Control Alberta
Phase 2 Recruiting
NCT00324415 2025-05-30
Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer
AIDS Malignancy Consortium
Phase 2 Completed
NCT02314169 2025-04-29
Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02437851 2025-04-11
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
AIDS Malignancy Consortium
Phase 2 Active not recruiting
NCT06630793 2025-04-08
IMPAC
Tata Memorial Centre
Phase NA Recruiting